AI Article Synopsis

  • * Subsequent tests, including a bone marrow biopsy and PET scan, led to the diagnosis of a solitary plasmacytoma (SP), which is a rare tumor type, highlighting the unusual presentation of the condition in a patient experiencing chest pain.
  • * The patient received localized radiation therapy for treatment, while also being monitored for the potential progression to multiple myeloma (MM), emphasizing the need for ongoing surveillance in such cases.

Article Abstract

A 45-year-old woman with a history of hypertension, polycystic ovary syndrome, and a family history of triple-negative breast cancer presented to our primary care clinic with an incidental fifth rib mass on a computed tomography (CT) scan of the chest. She reported mild intermittent left-sided chest pain and no constitutional symptoms. One year prior, she had a workup for a breast lesion, which was negative for breast cancer. Two months later, a repeat chest CT and a skeletal bone survey revealed an expansile and destructive left fifth rib lytic lesion concerning multiple myeloma (MM) but no other bony lesions. Serum protein electrophoresis revealed elevated IgA levels, free kappa light chains, and an M spike. A bone marrow biopsy showed an increase in plasma cells but with no clonality. A whole-body positron emission tomography (PET) scan was negative for other bony lesions or other solid tumors. A CT-guided biopsy of the left fifth rib revealed a solitary plasmacytoma (SP). This case study portrays a rare site for an SP and raises clinical awareness for the condition in patients presenting with atypical chest pain. The patient underwent localized radiation therapy, which is the mainstay of treatment for patients with this condition. Patients should also be monitored periodically for progression to MM if diagnosed and treated for an SP.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11608113PMC
http://dx.doi.org/10.7759/cureus.72787DOI Listing

Publication Analysis

Top Keywords

breast cancer
8
chest pain
8
left rib
8
bony lesions
8
condition patients
8
atypical presentation
4
presentation plasmacytoma
4
plasmacytoma young
4
young woman
4
woman 45-year-old
4

Similar Publications

Insights into NEK2 inhibitors as antitumor agents: From mechanisms to potential therapeutics.

Eur J Med Chem

January 2025

Department of Respiratory and Critical Care Medicine, Targeted Tracer Research and Development Laboratory, Institute of Respiratory Healthand, Department of Frontiers Science Center for Disease-related Molecular Network, Core Facilities, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China. Electronic address:

NEK2, a serine/threonine protein kinase, is integral to mitotic events such as centrosome duplication and separation, microtubule stabilization, spindle assembly checkpoint, and kinetochore attachment. However, NEK2 overexpression leads to centrosome amplification and chromosomal instability, which are significantly associated with various malignancies, including liver, breast, and non-small cell lung cancer. This overexpression could facilitate tumor development and confer resistance to therapy by promoting aberrant cell division and centrosome amplification.

View Article and Find Full Text PDF

Analysis of circulating cell-free nuclear and mitochondrial DNA in plasma of Mexican patients with breast cancer.

Gac Med Mex

January 2025

División de Medicina Molecular, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Guadalajara.

Background: The usefulness of circulating free DNA (cfDNA), nuclear DNA (nDNA) and mitochondrial DNA (mtDNA) as potential biomarkers in cancer remains controversial.

Objective: To determine the concentration of cfDNA and plasma nDNA and mtDNA levels in breast cancer (BC) patients.

Material And Methods: This study included a total of 86 women (69 patients with BC and 17 women as a control group).

View Article and Find Full Text PDF

MTHFD2 promotes breast cancer cell proliferation through IFRD1 RNA m6A methylation-mediated HDAC3/p53/mTOR pathway.

Neoplasma

December 2024

Department of Pathology and Forensic Medicine, College of Basic Medical Sciences, Dalian Medical University, Dalian, China.

MTHFD2 is highly overexpressed in breast cancer tissues, indicating that it might be used as a target in breast cancer treatment. This study aims to determine the role of MTHFD2 in breast cancer cell proliferation and the molecular pathways involved. In order to investigate MTHFD2 gene expression and its downstream pathways in breast cancer, we started our inquiry with a bioinformatics analysis.

View Article and Find Full Text PDF

Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast malignancy. Although some patients benefit from immune checkpoint therapy, current treatment methods rely mainly on chemotherapy. It is imperative to develop predictors of efficacy and identify individuals who will be sensitive to particular treatment regimens.

View Article and Find Full Text PDF

Background: CT thorax, abdomen and pelvis (CT-TAP) remains the standard in the identification of metastatic disease in patients with newly diagnosed breast cancer. In patients with proven micro and macro axillary nodal metastasis, the optimal radiological technique remains controversial. A consensus on which patients with axillary nodal disease should receive radiological staging for distant disease and how this should be performed is not currently available.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!